A 65-year-old man who had been experiencing diplopia in front and down gaze for 15 days visited our hospital. Hypertropia was noted in the patient's left eye, and limitation of depression was found in the adduction, primary gaze, and abduction. Brain magnetic resonance imaging showed no remarkable findings. Two weeks after the first visit, the patient complained of ptosis in the left eye. An ice test was performed and the ptosis was resolved after the test. Then, anti-acetylcholine receptor binding antibody levels were checked and found to be slightly elevated. We prescribed methylprednisolone per os 24 mg for 2 weeks, and his symptoms improved after the 2-week treatment. Five weeks after his first visit, the patient showed an ortho result in the alternate prism cover test and normal ocular movements. This may be the first case in which ocular myasthenia gravis presented as double depressor palsy, and in such cases, the possibility of ocular myasthenia gravis should be considered to rule out double depressor palsy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958640 | PMC |
| http://dx.doi.org/10.3341/kjo.2014.28.2.194 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Infectious Thoracoabdominal Aortic Aneurysm Repair in a Patient with Myasthenia Gravis: A Case Report.
Ann Vasc Dis
December 2024
Department of Cardiovascular Surgery, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Myasthenia gravis (MG) is an autoimmune neuromuscular junction disorder that rarely coexists with infectious thoracoabdominal aortic aneurysms (TAAA) requiring open repair. A 57-year-old patient with MG underwent elective thoracoabdominal aortic replacement. He was diagnosed with MG (Osserman classification II A).
View Article and Find Full Text PDFRethinking the diagnostic value of thymic CT in ocular myasthenia gravis.
Acta Neurol Belg
December 2024
Department of Neurology, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu, 41944, Republic of Korea.
[Subcutaneous Injection of Efgartigimod, a New Therapeutic Agent for Generalized Myasthenia Gravis].
Brain Nerve
January 2025
Department of Neurology, Graduate School of Medicine, Chiba University.
Patients with generalized myasthenia gravis (gMG) suffer from significant physical and social burdens. Although immunotherapies have been widely used for the treatment of gMG, some patients do not achieve or maintain remission. Recently, several molecular-targeting therapies of gMG, including the intravenous infusion of efgartigimod alfa (efgartigimod IV), a neonatal Fc receptor inhibitor, have been developed and are clinically used in Japan.
View Article and Find Full Text PDFThe clinical significance of open vs. minimally invasive surgical approaches in the management of thymic epithelial tumors and myasthenia gravis.
Front Surg
December 2024
Division of Thoracic Surgery, Department of Surgery, Kaiser Permanente Northern California, Oakland, CA, United States.
Though advancements have been made in the pharmacologic treatment of myasthenia gravis (MG), surgical resection is not only an option as a last line of defense for those patients who do not respond to medical therapy but also remains vital for those with thymic epithelial tumors (TET). While prior studies have shown the potential superiority of minimally invasive approaches via robotic- and video-assisted thoracoscopic surgery (RATS/VATS) for thymectomy compared to open surgery, in the setting of malignancies, this outcome delineation is controversial. As RATS/VATS may be associated with less post-operative complications in the treatment of TET, some surgeons argue that the open approach is necessary for complete resection (R0 resection) and to prevent potential seeding of the malignancy.
View Article and Find Full Text PDFImpact of SARS-CoV-2 infection on patients with myasthenia gravis: a retrospective study in a Chinese population.
Front Neurol
December 2024
Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang, Shijiazhuang, China.
Background And Purpose: Myasthenia gravis (MG) is characterized by fluctuating muscle weakness due to immune-mediated damage to acetylcholine receptors. Viral infections can exacerbate symptoms of muscle weakness, and the clinical status of patients with MG may influence the outcomes of such infections. Here, we identified factors of symptom exacerbation, severe SARS-CoV-2 infection, and pneumonia in patients with MG who are infected with SARS-CoV-2.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!